A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-period Cross-over Study to Evaluate the Scopolamine Cognition Model in Healthy Male Subjects Using AZD1446 and Donepezil Versus Placebo

The purpose of this study is to determine if cognitive impairment induced by scopolamine is reversed using donepezil and/or AZD1446 as compared to placebo, as assessed by electroencephalogram (EEG) measures.

Inclusion Criteria:

• BMI 18-30
• Non-smoker for at least 4 weeks

Exclusion Criteria:

• Any clinically relevant acute or chronic disease
• Hypersensitivity to scopolamine
• History of substance abuse